This book highlights the role of the Translationally Controlled Tumor Protein (TCTP) in cell signaling, cell fate and the resulting connection to disease development. It begins by discussing the structure/function of TCTP, before exploring its role in different species ranging from plants to Drosophila and covering fields such as development, the cytoskeleton, cell division, DNA fragility and apoptosis. In turn, the book's final section is devoted to the role of TCTP in disease, namely asthma and diverse cancers, and ultimately as a target for the treatment of malignancies. What is the common denominator between all these processes and why is TCTP necessary in order for them to occur, even in the worst case such as cancer? The book seeks to provide meaningful answers to this and other key questions. Presenting a broad and revealing view on the topic, it offers an informative guide for scientists and students alike.

This volume will outline how to recreate the tumor microenvironment, to culture primary tumors without the need for developmental priming factors, and to deliver targeted therapeutics in a manner that recapitulates pharmacokinetics in vivo. Much of what may be learned from this volume will aid in understanding many aspects of the enhanced study of tumor cell biology in a physiologic context, open new avenues for drug screening and biomarker development, and accelerate the preclinical evaluation of novel personalized medicine strategies for patients in real time.

It's in Your DNA: From Discovery to Structure, Function and Role in Evolution, Cancer and Aging describes, in a clear, approachable manner, the progression of the experiments that eventually led to our current understanding of DNA. This fascinating work tells the whole story from the discovery of DNA and its structure, how it replicates, codes for proteins, and our current ability to analyze and manipulate it in genetic engineering to begin to understand the central role of DNA in evolution, cancer, and aging. While telling the scientific story of DNA, this captivating treatise is further enhanced by brief sketches of the colorful lives and personalities of the key scientists and pioneers of DNA research. Major discoveries by Meischer, Darwin, and Mendel and their impacts are discussed, including the merging of the disciplines of genetics, evolutionary biology, and nucleic acid biochemistry, giving rise to molecular genetics. After tracing development of the gene concept, critical experiments are described and a new biological paradigm, the hologenome concept of evolution, is introduced and described. The final two chapters of the work focus on DNA as it relates to cancer and gerontology. This book provides readers with much-needed knowledge to help advance their understanding of the subject and stimulate further research. It will appeal to researchers, students, and others with diverse backgrounds within or beyond the life sciences, including those in biochemistry, genetics/molecular genetics, evolutionary biology, epidemiology, oncology, gerontology, cell biology, microbiology, and anyone interested in these mechanisms in life.

This book aims to provide scientists with tools and well-researched protocols to enable their research and to facilitate further progress in this common leukemia. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Chronic Lymphocytic Leukemia: Methods and Protocols aims to accelerate research on chronic lymphocytic leukemia and further improvements in patient outcomes.

The set of techniques known collectively as real-time data capture (RTDC) is becoming increasingly important in medical research. Based on the collection of data in people's typical environments, RTDC is primarily used with self-reported data, such as medical symptoms and psychological states. Now, its guiding principles and supporting technologies also provide a framework for scientists to monitor physiological information such as heart rate, blood pressure, and skin conductance. This volume gives the most complete view yet of the state of RTDC science and its potential for use across the health and behavioural sciences.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Cathy Eng, is devoted to Anal Canal Cancers. Dr. Eng has assembled expert authors to review the following topics: Epidemiology of Anal Canal Cancers; Management of Anal Dysplasia; Diagnosis and Diagnostic Imaging of Anal Canal Cancers; Pathology of Anal Canal Cancers; Treatment of the Primary Tumor in Anal Canal Cancers; Acute and Chronic Toxicities of Radiation Therapy for Anal Canal Cancers; Locally Recurrent Disease Related to Anal Canal Cancers; Surveillance of Anal Canal Cancers; Metastatic Anal Cancer and Novel Agents; Treatment of Oligometastatic Disease; Unusual Anal Cancers: Melanoma and Carcinoid; Patient Perspective and Personal Journey of Treating a "Rare Cancer"; HIV/AIDS, HPV, and Anal Cancer; Pathology of Anal Cancer, and more!

This book describes the most important techniques used for studying cfDNA in the different samples; serum, plasma, urine. Chapters detail methods on liquid biopsy for cancer disease, methods in cancer, epigenetic modifications, fetal and pediatric diseases, physical activity, and urinary cell free DNA. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Cell-Free DNA as Diagnostic Markers: Methods and Protocols aims to ensure successful results in the further study of this vital field.

This astute volume brings together the latest expert research on adamantinomatous craniopharyngiomas (ACPs). ACPs are histologically benign but clinically aggressive tumors exhibiting a high propensity for local invasion into the hypothalamus, optic and vascular structures. These tumors, as well as the current treatments, may result in pan-hypopituitarism, diabetes insipidus, morbid obesity followed by type II diabetes mellitus, blindness, as well as serious behavioral and psychosocial impairments. Exploring in detail advances in both the understanding of tumor biology as well as clinical advances in patient management are explored in detail, this book will also look towards potential new treatment approaches. Basic Research and Clinical Aspects of Adamantinomatous Craniopharyngioma is the first book compiling all current research on ACPs. Mouse and human studies have unequivocally demonstrated that mutations in CTNNB1 encoding -catenin underlie the etiology of the majority, if not all ACP tumors. Genetic studies in mice have shown that ACPs are tumors of the pituitary gland and not of the hypothalamus as previously thought, and are derived from Rathke's pouch precursors. In addition, a role for tissue-specific adult pituitary stem cells has been revealed as causative of ACP. Together, these studies have provided novel insights into the molecular and cellular etiology as well as the pathogenesis of human ACP. Finally, this volume covers new treatment approaches that have been shown to be effective both in reducing ACP burden as well as reducing the morbidity associated with therapy.

This issue of Surgical Clinics of North America, guest edited by Dr. Jeffrey M. Hardacre, is devoted to Pancreatic Cancer and Periampullary Neoplasms. He has assembled expert authors to review the following topics: Genetics of Pancreatic Cancer and its Implication on Therapy; Familial Pancreatic Cancer and Screening of High-risk Individuals; Imaging Evaluation of Pancreatic Cancer; Endoscopic Evaluation in the Work-up of Pancreatic Cancer; Definition and Management of Borderline Resectable Pancreatic Cancer; Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer Surgery; Surgical Therapy for Pancreatic and Periampullary Cancer; Post-Pancreatectomy Complications and Management; Adjuvant and Neoadjuvant Therapy for Resectable Pancreatic and Periampullary Cancer; Management of Locally Advanced Pancreatic Cancer; Management of Metastatic Pancreatic Cancer; Management of Pancreatic Neuroendocrine Tumors; Management of Intraductal Papillary Mucinous Neoplasms; Palliative Care and Surgery in Pancreatic Cancer; Enhanced Recovery Pathways in Pancreatic Cancer; and more!

This volume aims to provide a range of methods and protocols for studying tumor angiogenesis in vitro and in vivo to reflect advances in the field. The chapters in this book cover topics such as: morphological aspects of tumor angiogenesis, aortic ring assay and its use for the study of tumor angiogenesis, ex vivo tissue culture model for anti-angiogenic drug testing, transgenic zebrafish, orthotopic models of ovarian cancer, and uncovering metabolic effects of anti-angiogenic therapy in tumors by induced metabolic bioluminescence imaging. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Tumor Angiogenesis Assays: Methods and Protocols is a valuable resource for anyone interested in tumor angiogenesis assay research.

Breast cancer research has never been in such an exciting and hopeful phase as today. From a clinical perspective, the discovery of genetic markers of risk in a proportion of familial breast cancer cases has opened up new vistas for understanding and ultimately preventing this disease. On the other hand, aggressive - even daring - therapies are being proven to be effective against advanced breast cancer. For the breast cancer experimentalist, this is also a time of great advance. Although animal and cell culture breast cancer models have proven to be of great use, there are now increasing opportunities to test the concepts developed in these models in actual clinical samples and cases. It is gratifying to see how well these concepts "translate" into the clinical setting. A very active area of research that is linking the laboratory to the clinic is the dissection of the biology and elucidation of the significance of proliferate breast disease and the identification of true, "high risk" or "preneoplastic" legions within the previously ill-defined spectrum of fibrocystic or benign breast disease. One anticipates that discoveries made here will also lead to earlier detection, intervention and prevention of life-threatening cancer.
Even, however, as we look with optimism to the eventual eradication of breast cancer, we are once again forced to face the reality that we have not yet achieved our goal. Thus, we are saddened by the much too premature death of Dr. Helene Smith from breast cancer. Helena's work was at the forefront of efforts to understand the biology of human breast cancer at the molecular level. Her insight, open-mindedness, and refusal to sacrifice relevance for convenience will continue to set the standard for all breast cancer researchers. This volume is dedicated to her memory.

This issue of Surgical Clinics of North America, guest edited by Drs. Jeffrey M. Farma and Andrea Porpiglia, is devoted to Sarcoma. They have assembled expert authors to review the following topics: Epidemiology and Etiology of Sarcomas; Management of Extremity Sarcomas; Management of Retroperitoneal Sarcomas; Management of Dermatofibrosarcoma Protuberans; Management of Desmoids; Management of Truncal Sarcomas; Management of Bone Sarcomas; Management of Pediatric Sarcomas; Local Recurrence of Sarcomas; Management of Metastatic Disease; Imaging of Sarcomas; Management of Gastrointestinal Stromal Tumors; Management of Breast Sarcoma; Chemotherapy for Sarcomas; Pathology and Classification of Sarcomas; Radiation Therapy for Sarcomas; and more!

Childhood acute leukemias are one of the main causes of death in children aged 1 to 14 years in some countries; and unfortunately, we have been unable to prevent it. Certainly, a good parcel of it is due to the poor understanding about its etiology. This book aims to describe the most important theories and hypothesis regarding childhood acute leukemia. Written by the most outstanding researchers in the field, this book intends to contribute to a greater understanding of the etiology of this disease. It goes beyond the simple and common analysis of risk factors, which hardly allows us to draw definite conclusions. By addressing the etiology of the disease, discussing from molecular biology until epidemiology and clinical manifestations, this book will guide present and future approaches, contributing for a better clinical management of leukemia in children. The knowledge regarding etiology is a crucial step for a better evaluation, prevention and treatment of a disease. Thus, this book finally intends to provide such knowledge, allowing physicians and practitioners to a better manage of childhood acute leukemias.

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.

This issue of Hematology/Oncology Clinics will cover aggressive B-Cell Lymphoma and articles to be included are: State of the art therapy for advanced stage DLBCL; DLBCL: Should limited stage patients be treated differently; Role of PET in DLBCL; Management of relapsed DLBCL; The spectrum of double-hit lymphoma; Optimizing outcomes in primary mediastinal B cell lymphoma; The grey zone of unclassifiable lymphomas; as well as many more.

The book conveys a comprehensive knowledge of long and short ncRNAs in cancer regulation and their potentials as diagnostic biomarkers and therapeutic targets. Topics covered include the molecular mechanisms of various classes of ncRNAs (with emphasis on long non-coding RNAs and microRNAs) in cancer, the functional roles of ncRNAs in regulating different cancer hallmarks (including proliferation, apoptosis, stem-cell properties, epithelial-mesenchymal transition, metabolism, angiogenesis, tumor-host interactions and therapeutic resistance), the role of ncRNAs in regulating cancer signaling circuitry programs (highlighting their involvement in c-myc, p53 and NFkB signaling), a systemic summary of clinical and preclinical studies that evaluate the potential of ncRNA signatures for cancer diagnosis and prognosis and strategies to delivery short ncRNAs as therapeutic molecules for cancer treatment. This book may serve as a comprehensive resource for researchers, graduate students and oncologists in ncRNA and cancer research and help drug development by identifying ncRNA targets.

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Chandrajit P. Raut, is devoted to Sarcomas. Dr. Raut has assembled expert authors to review the following topics: Sarcoma: Histologic Subtypes and Changes in the Recent WHO Classification; Distinguishing Radiologic Characteristics of Sarcoma Histologic Subtypes; Extremity Soft Tissue Sarcoma: Tailoring Resection to Histologic Subtype; Retroperitoneal Sarcoma: Fact, Opinion, and Controversy; Breast Sarcoma; Management of Sarcoma Metastases to the Lung; Gastrointestinal Stromal Tumor; Liposarcoma: Surgical Management and Future Targeted Therapy; Myxofibrosarcoma; Malignant Peripheral Nerve Sheath Tumor; Desmoid Fibromatosis: Evolving Treatment Standards; Dermatofibrosarcoma Protuberans: Surgery v. Mohs; Radiation Therapy: Indications and Controversies for Neoadjuvant Therapy, Adjuvant Therapy, IORT, and Brachytherapy; Chemotherapy: Does Neoadjuvant or Adjuvant Therapy Improve Outcomes?; and more!

This issue of Surgical Oncology Clinics of North America, guest edited by Dr. Mark Krasna, is devoted to Lung Cancer. Dr. Krasna has assembled expert authors to review the following topics: Epidemiology for Lung Cancer; Screening for Lung Cancer; Pathology for Lung Cancer; Treatment of Patients with Oligometastatic Disease for NSCLC; SBRT/Ablative Therapies for NSCLC; Mediastinal Staging for Lung Cancer; VATS Lobectomy for NSCLC; Robotic Lung Resection for NSCLC; Pneumonectomy for NSCLC; Bronchoscopy-Diagnostic and Therapeutic for NSCLC; Neoadjuvant Therapy for Lung Cancer; Molecular/Targeted Therapy for Lung Cancer; Adjuvant Therapy for Stage 1and 2 NSCLC, and more!

This issue of Neuroimaging Clinics of North America focuses on Adult Brain Tumors, and is edited by Dr. Lara Brandao. Articles will include: Posterior Fossa Tumors in Adult Patients; Lymphomas and Adult Brain Tumors; Pre-Treatment Evaluation of Gliomas; Post Treatment Evaluation of Gliomas; Metastasis in Adult Brain Tumors; Extraparenchymal Lesions in Adult Brain Tumors; Interesting Case Studies in Adult Brain Tumors; Advanced MR Imaging Techniques in Daily Practice; and more!

This book is the first to focus specifically on cancer nanotheranostics. Each of the chapters that make up this comprehensive volume is authored by a researcher, clinician, or regulatory agency member known for their expertise in this field. Theranostics, the technology to simultaneously diagnose and treat a disease, is a nascent field that is growing rapidly in this era of personalized medicine. As the need for cost-effective disease diagnosis grows, drug delivery systems that can act as multifunctional carriers for imaging contrast and therapy agents could provide unique breakthroughs in oncology. Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response and initiate secondary treatments if required. In oncology, chemotherapeutics have been routinely used. Some drugs have proven effective but all carry risks of adverse side effects. There is growing interest in using remotely triggered drug delivery systems to limit cytotoxicity in the diseased area. This book reviews the use of theranostic nanoparticles for cancer applications over the past decade. First, it briefly discusses the challenges and limitations of conventional cancer treatments, and presents an overview of the use of nanotechnology in treating cancer. These introductory chapters are followed by those exploring cancer diagnosis and a myriad of delivery methods for nanotherapeutics. The book also addresses multifunctional platforms, treatment monitoring, and regulatory considerations. As a whole, the book aims to briefly summarize the development and clinical potential of various nanotheranostics for cancer applications, and to delineate the challenges that must be overcome for successful clinical development and implementation of such cancer theranostics.

Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.

This volume provides detailed descriptions of prevailing and novel techniques used by experts in the study of PTEN function in disease and biology. The book begins with chapters exploring methods to detect expression levels of PTEN in normal and diseased human specimens; methods to evaluate specific PTEN function in brain cancer; methods that utilize a new biosensor to measure PTEN regulation; and techniques to measure post-transcriptional regulation of PTEN by micoRNAs and ceRNAs. Other chapters present methods describing novel techniques to detect PTEN localization and previously unstudied structural features of PTEN measured through X-Ray Crystallography and Hydrogen Deuterium Exchange Mass Spectrometry. The book concludes with methods to study PTEN function in model organisms including mice and C. elegans. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and thorough, PTEN: Methods and Protocols is a valuable collection of methodologies and protocols useful to researchers who are interested in the PTEN field.

After nearly three decades of providing medical care for women and men facing breast cancer, surgeon S. David Nathanson calls the survival rates today an ordinary miracle. Ordinary because the vast majority of patients now do live at least 20 years after diagnosis due to enormous progress that has been made in medicine; and a miracle too because of the intangible qualities such as faith and hope that seem key to success in battling the disease. In this book, survivors describe their experiences, emotions, and means to overcome the disease. S. David Nathanson is an esteemed, longtime surgeon who calls the survival rates today for women and men facing breast cancer nothing short of an ordinary miracle. Ordinary because the vast majority of patients live at least two decades after diagnosis, due to great advances that have been made in early detection, surgery, radiation, and chemotherapy. But also a miracle because we know that key elements for a woman or man succeeding in a personal battle against breast cancer include completely intangible qualities of courage, fortitude, trust, persistence, faith, and hope. Although science cannot completely explain it, a supportive network of family and friends with those qualities also empower patient survival and recovery. In these pages, Nathanson shares stories from his patients, teaching us about the experience of breast cancer and explaining how they found and fueled the will and power to defeat the disease. Even surgeon Nathanson himself cannot fully describe what goes through the hearts and minds of breast cancer patients as they discover, deal with, and finally triumph over the diagnosis. So in this book he acts as a narrator, letting his ordinary yet miraculous cancer survivors tell their stories, certainly filled with fear of the known and unknown, and with pain, but opening up to courage, love, sometimes humor, and finally hope. It is hope that firms up their resilience; hope that initiates their fortitude. Hope is an important component of healing, says the surgeon. Seventy-one survivors, including one man, tell their stories to ilustrate every step of the experience.